Ireland's central source for Open Access health research
Lenus, the Irish Health Research repository is the leading source for Irish research in health and social care. The Lenus collections include peer reviewed journal articles, grey literature, dissertations, reports and conference presentations. Lenus contains the publications of the Irish Health Service Executive (HSE) and the collected research output of over 130 health organisations past and present are all freely accessible.
Submit Your Research to Lenus
If you are an Irish Researcher or have conducted research in an Irish Institution or Health Organisation you can add your published research to Lenus. Submitted articles must be available in Open Access format or the publishers policy permit author self archiving. Advice on Open Access publishing and publishers policies are available on the 'Open Access Publishing Guide' and 'publishers' policies' pages available on the left.
HSE Open Access Research Awards 2018 - Now Open for Entry
Aplications are now open for the annual HSE Open Access Research awards. If you have published in Open Access in the past 24 months you can now submit. Applications will be accepted until November 2nd and winners will be announced at the Open Access Awards ceremoney on December 7th
Sign up for Lenus Spotlights
The Lenus spotlights email newsletter delivers the pick of recent Lenus articles and reports plus news on open access events directly to your inbox.
Communities in DSpace
Select a community to browse its collections.
Biosimilar infliximab introduction into the gastroenterology care pathway in a large acute Irish teaching hospital: a story behind the evidence(Pro Pharma Communications International, 2018-02-27)Background and aim: Biosimilar medicines are not considered exact replicas of originator biological medicines. As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence surfaces confirming their safety and effectiveness. In Ireland, a national biosimilar medicines policy is currently in development but the decision to prescribe biosimilar medicines remains at the discretion of the physician. The aim of this descriptive review is to tell the story of the evidence used by a large acute Irish teaching hospital to introduce biosimilar infliximab CT-P13 for the treatment of inflammatory bowel disease (IBD) in a safe and timely manner into routine care. Methods: To explore the evidence supporting the effective introduction of biosimilar infliximab in a large acute Irish teaching hospital, a literature review was conducted. Evidence consisted of published studies, reviews, reports, position statements, articles, clinical guidelines, and recommendations from national bodies, regulatory authorities and professional organizations. All evidence was published in English. Results and discussion: In September 2014, the accumulated evidence base provided physicians with reassurance to prescribe biosimilar infliximab CT-P13 for new patients suffering from IBD in this large acute Irish teaching hospital. In September 2016, as the evidence base grew, physicians began to safely and confidently switch patients from the originator infliximab product to the biosimilar product. Conclusion: There was a significant time lag between regulatory approval and clinical acceptance given that the European Medicines Agency had granted market authorization for biosimilar infliximab CT-P13 three years prior to the initiation of this hospital’s switching process. Although conservative in their execution, the authors conclude that with the existential concern and uncertainty still surrounding biosimilar medicines, a distinct and individualized approach for biosimilar medicine implementation is required. It is with hope that the Irish biosimilar medicines policy will improve upon biosimilar medicine clinical acceptance once published.